



**MassHealth**  
**Managed Care Entity Bulletin 73**  
**November 2021**

**TO:** Managed Care Entities and PACE Organizations Participating in MassHealth

**FROM:** Amanda Cassel Kraft, Assistant Secretary for MassHealth

**RE: Coverage for Monoclonal Antibodies for Treatment and Post-Exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19)**

### **Applicable Managed Care Entities and PACE Organizations**

- Accountable Care Partnership Plans (ACPPs)
- Managed Care Organizations (MCOs)
- MassHealth's behavioral health vendor
- One Care Plans
- Senior Care Organizations (SCOs)
- Program of All-inclusive Care for the Elderly (PACE) Organizations

### **Overview**

This bulletin supplements and updates Managed Care Entity Bulletins 50 and 57. Managed care plans, as defined in [MCE Bulletin 50](#)<sup>1</sup>, when providing monoclonal antibody products for treatment and post-exposure prophylaxis for COVID-19 as Medicaid services, must conform their coverage policies, including rates of payments, to match those in [All Provider Bulletins 318 and 326](#).

PACE organizations must ensure their coverage policies include those in All Provider Bulletins 318 and 326 when providing monoclonal antibody products for treatment and post-exposure prophylaxis for COVID-19 to PACE participants.

### **Updated Coverage and Payment for COVID-19 Monoclonal Antibody Products**

All Provider Bulletin 318 updates MassHealth requirements for coverage of monoclonal antibody product infusion, including but not limited to service codes, billing instructions, and rates of payment, and sets forth U.S. Food and Drug Administration (FDA) actions on certain products. All Provider Bulletin 326 provides additional codes and payment rates for hospital outpatient, community health centers and physician practices for the administration of monoclonal antibodies

---

<sup>1</sup> As described further in MCE Bulletin 50, One Care plans and SCOs should first follow guidance provided by Medicare on these topics for enrollees with Medicare, including billing and coding instructions. SCOs must follow the requirements in this bulletin for Medicaid-only enrollees. PACE organizations should follow all Medicare and CMS guidance issued on these topics that is applicable to PACE.

**MassHealth  
Managed Care Entity Bulletin 73  
November 2021  
Page 2 of 2**

as post-exposure prophylaxis and updates existing code descriptions to match current Healthcare Common Procedure Coding System (HCPCS) descriptions reflecting that certain monoclonal antibody products may be administered through subcutaneous injection as well as intravenous infusion.

Managed care plans, as defined in Managed Care Bulletin 50, must conform their coverage policies, including rates of payments, to match those in All Provider Bulletins 318 and 326, when providing monoclonal antibody products for treatment and post-exposure prophylaxis for COVID-19 as Medicaid services.

PACE organizations must conform their coverage policies to match those in All Provider Bulletins 318 and 326, when providing monoclonal antibody products for treatment and post-exposure prophylaxis for COVID-19 to PACE participants.

### **MassHealth Website**

This bulletin is available on the [MassHealth Provider Bulletins](#) web page.

[Sign up](#) to receive email alerts when MassHealth issues new bulletins and transmittal letters.

### **Questions**

If you have any questions about the information in this bulletin, please contact the MassHealth Customer Service Center at (800) 841-2900, email your inquiry to [providersupport@mahealth.net](mailto:providersupport@mahealth.net), or fax your inquiry to (617) 988-8974. Managed care plans should submit written questions and comments concerning this bulletin to their contract managers.